Biopharmaceutical company Immunic, Inc. announced that it has been granted a key European patent, which will provide important protection for the administration regimen related to Vidofludimus calcium.
Show original
The granting of this patent further consolidates the company's intellectual property position in the development of this innovative therapy.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
US Senator: Parties May Need to Compromise on Stablecoin "Clarity Act"
金色财经•2026/03/10 15:24
Trending news
MoreBlockstream's Jade hardware wallet adds Lightning Network support, enabling instant bitcoin payments from cold storage.
Ortelius Capital Management recently proposed a series of strategic adjustments for Surgery Partners, Inc., including a comprehensive overhaul of the board structure, the introduction of a new management team, and a systematic evaluation of the company’s current development strategy.
Crypto prices
MoreBitcoin
BTC
$71,158.84
+3.01%
Ethereum
ETH
$2,068.89
+2.19%
Tether USDt
USDT
$1
+0.01%
BNB
BNB
$648.73
+1.93%
XRP
XRP
$1.42
+4.38%
USDC
USDC
$1
+0.00%
Solana
SOL
$87.78
+3.07%
TRON
TRX
$0.2845
-0.19%
Dogecoin
DOGE
$0.09823
+7.46%
Cardano
ADA
$0.2705
+5.43%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now